GENE ONLINE|News &
Opinion
Blog

2020-08-31| In-DepthR&DSpecial

Spotlight: Infusion-Related Reactions Associated with Rapid Infusion of Daratumumab

by GeneOnline
Share To
Daratumumab, an anti-CD38 monoclonal antibody, has revolutionized the treatment outcome and prognostic expectations in patients with relapsed myeloma. The USFDA approved it in November 2015 for treating patients with relapsed refractory multiple myeloma (RRMM) and those with newly diagnosed multiple myeloma (MM) who are ineligible for stem cell transplant.

Daratumumab, as the newest class of therapeutics for MM, has demonstrated substantial clinical efficacy and rapid and durable response in patients with RRMM who relapse after initial therapy or are refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) [1,2].

GO Prime with only $1.49 now

LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top